David Beckham‘s backed health firm Prenetics Global Limited announced a major strategic shift on December 30, 2025, halting Bitcoin purchases to focus entirely on IM8, the premium supplement brand. The company stopped daily cryptocurrency acquisitions on December 4, 2025, marking a dramatic pivot from its aggressive crypto treasury strategy implemented just months earlier.
🔥 Quick Facts
- Prenetics stopped Bitcoin purchases on December 4, 2025, ending its crypto treasury strategy
- The company maintains 510 Bitcoin holdings valued at approximately $27 million
- IM8 generates $9 million monthly with 420,000+ customers as of late 2025
- Prenetics targets $1 billion annual revenue by focusing solely on the supplement brand’s expansion
Strategic Pivot Away From Cryptocurrency Holdings
Intuit emerges as best software stock for 2026 while stock crashes to bargain levels analysts didn’t expect
2026 tax brackets shock Americans with hidden paycheck truth nobody expected
Prenetics officially ceased its cryptocurrency purchase strategy after just six months of aggressive Bitcoin accumulation. In June 2025, the Nasdaq-listed health sciences firm made headlines by investing $20 million in Bitcoin, becoming the first public healthcare company to announce a formal crypto treasury strategy.
The company’s decision reflects a dramatic change in priorities. Board approval came through for the shift, directing capital toward IM8 supplement expansion instead. Prenetics CEO Danny Yeung and co-founding partner David Beckham refocused the company’s resources on their explosive health nutrition venture, which has surged far beyond initial projections.
IM8 Growth Shatters Industry Records
Marcus Lemonis takes CEO role at Bed Bath & Beyond with $25M cost-cutting plan and watch what industry experts are saying about his next move
SPX surges 34 points at open with shocking tech recovery, here’s what caused the unexpected Venezuela rally
The IM8 supplement brand achieved unprecedented market success in under a year. Launched in November 2024 in partnership with David Beckham, the health supplement brand reached $100 million in annual recurring revenue within 11 months—an industry-first achievement. The Daily Ultimate Essentials powder product combines 92 nutrient-rich ingredients replacing 16 traditional capsules.
By Q3 2025, IM8 was tracking toward $120 million annual recurring revenue, according to Prenetics’ third-quarter earnings report. The supplement brand serves 420,000+ customers and generates approximately $9 million monthly. World No. 1 tennis player Aryna Sabalenka became the first current athlete shareholder in Prenetics, further validating the brand’s market position.
| Business Metric | Performance |
| Time to $100M ARR | 11 months (industry record) |
| Q3 2025 Projection | $120M Annual Recurring Revenue |
| Monthly Revenue (Late 2025) | $9 million |
| Active Customers | 420,000+ |
| Flagship Product | Daily Ultimate Essentials with 92 nutrients |
Bitcoin Treasury Strategy Abandonment And Capital Reallocation
The October 2025 fundraising round brought $48 million in fresh capital to Prenetics, backed by cryptocurrency leaders Kraken and Exodus. With warrant exercise potential, the round could reach $216 million. However, Prenetics’ board determined that aggressive Bitcoin accumulation diverted focus from IM8‘s explosive growth opportunity.
Prenetics will maintain its current Bitcoin holdings valued at approximately $27 million but cease future acquisitions. The company’s five-year revenue target remains $1 billion annually, achievable exclusively through supplement brand dominance. David Beckham, as strategic partner, aligns the company’s growth narrative with premium nutrition market leadership rather than cryptocurrency speculation.
Market Position And Competitive Advantage
IM8 entered the $187 billion global supplement industry with a differentiated approach. The brand secured NSF Certified for Sport designation for its Daily Ultimate Essentials product, validating safety and purity standards. Mayo Clinic partnerships and endorsements from elite athletes like Aryna Sabalenka establish credibility within health-conscious consumer segments.
The supplement market saw Prenetics scale faster than competitors like AG1 under prior iterations. IM8‘s positioning emphasizes premium core nutrition replacing fragmented supplement stacks. David Beckham‘s personal commitment—using IM8 Daily Essentials as his daily routine—authenticates marketing claims beyond typical celebrity endorsements.
What Does This Pivot Mean For Prenetics’ Future Direction?
Prenetics Global Limited‘s strategic decision signals confidence in IM8 as the cornerstone growth engine. The company abandoned cryptocurrency treasury accumulation to channel capital into product development, global marketing expansion, and supply chain optimization. Prenetics management believes supplement market dominance delivers superior risk-adjusted returns compared to cryptocurrency volatility.
The bitcoin holdings represent a strategic reserve rather than active treasury growth. This pivot positions David Beckham and Prenetics as focused health-tech leaders rather than crypto-adjacent entities. As IM8 approaches $120+ million annual recurring revenue, the company’s valuation trajectory depends entirely on supplement brand execution, customer retention, and international expansion beyond U.S. markets.
Sources
- Bloomberg – David Beckham-Backed Health Firm Ceases Bitcoin Treasury Plans (December 30, 2025)
- Prenetics Global Limited – Official Capital Allocation Strategy Update (December 30, 2025)
- Investing.com – Prenetics Shifts Focus to IM8 Brand, Halts Bitcoin Purchases (December 30, 2025)
Patrick Graham is a business and finance journalist translating Wall Street’s complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world’s biggest moves.